The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
 
Ben Creelan
Consulting or Advisory Role - Achilles Therapeutics plc; AstraZeneca; ER Squibb & Sons, LLC; G1 Therapeutics, Inc; Iovance Biotherapeutics Inc; MJH Healthcare Holdings, LLC; Regeneron
Speakers' Bureau - AstraZeneca; Roche
Research Funding - Cancer Research Institute (Inst); Clinigen Group (Inst); E. R. Squibb & Sons, LLC (Inst); Turnstone Biologics Corp (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2020263919A1 pending; Patent WO2021163695A2 pending
Travel, Accommodations, Expenses - American Association for Cancer Research; AstraZeneca; ESMO; G1 Therapeutics, Inc; Regeneron; Roche; Society for the Immunotherapy of Cancer
Other Relationship - OmniHealth Media
 
Scott Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); NextCure (Inst)
 
Jason Chesney
Consulting or Advisory Role - Iovance Biotherapeutics; Iovance Biotherapeutics
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Ammar Sukari
Stock and Other Ownership Interests - Bristol-Myers Squibb/Pfizer; Immunomedics
Honoraria - Merck KGaA
Speakers' Bureau - Coherus Biosciences; MSD
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Sylvia Lee
Research Funding - Bristol-Myers Squibb; Iovance Biotherapeutics; Kite, a Gilead Company; Lyell Immunopharma; Seagen
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Atreca; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Hexagon; Hookipa Biotech; I-Mab; ITeos Therapeutics; LianBio; Lilly; Merck; Merus; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Sanofi; Seagan; Strata Oncology; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
Jorge Nieva
Leadership - AffyImmune Therapeutics
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L
Consulting or Advisory Role - AADi; ANP Technologies; AstraZeneca; Bioatla; Genentech; Gilead Sciences; Mindmed; Urogen pharma
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Juan Martin-Liberal
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Ipsen; Novartis; Pierre Fabre; Roche; Sanofi; Trialing Health
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche
 
Juan Francisco Rodriguez Moreno
Employment - HM Hospitales
Speakers' Bureau - AstraZeneca Rare Disease; Bristol Myers Squibb Foundation; Janssen; MSD; Novartis; Pfizer; Roche
Research Funding - Abbvie; Amgen; Aprea Therapeutics; Astellas Amgen BioPharama; AstraZeneca Rare Disease; Bayer; Bristol Myers Squibb Foundation; Eisai; GlaxoSmithKline; Iovance Biotherapeutics; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; AstraZeneca; Bristol Myers Squibb Foundation; MSD; Novartis; Pfizer; Roche
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen Oncology; Pfizer; Roche/Genentech; Sanofi
 
Bernard Doger de Spéville
No Relationships to Disclose
 
Debra Josephs
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Iovance Biotherapeutics; Ipsen; Janssen; MSD; Novartis; Pfizer
 
Geoffrey Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; HUYA Bioscience International; Immunocore; Iovance Biotherapeutics; Lyell Immunopharma; Merck; Novartis; Pfizer; Regeneron; Replimune
Speakers' Bureau - Immunocore
Research Funding - Exelixis (Inst)
 
Sajeve Thomas
Speakers' Bureau - Bms; Merck; Natera; Pfizer; SpringWorks Therapeutics
 
Yazan Samhouri
No Relationships to Disclose
 
Selda Samakoglu
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Minjie Feng
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Friedrich Finckenstein
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Adam Schoenfeld
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Enara Bio; Heat Biologics; Immunocore; Iovance Biotherapeutics; Johnson & Johnson/Janssen; KSQ Therapeutics; Legend Biotech; Lyell Immunopharma; Merck; Oppenheimer; Perceptive Advisors; Prelude Therapeutics; Umoja Biopharma
Research Funding - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
Travel, Accommodations, Expenses - Instil Bio; Iovance Biotherapeutics
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma